In this podcast, an advanced practice provider discusses the latest guidance on integrating CDK4/6 inhibitors into treatment of early-stage and metastatic HR+/HER2- breast cancer. Cases from her practice illustrate how to approach treatment selection and manage important adverse events.
Oncology NPs, PAs, and nurses
This activity is supported by an educational grant from Lilly.
Julia LaBarbera, MSN, RN, AGACNP-BC: consultant/advisor/speaker: Biotheranostics, MJH Life Sciences.
© 2022 Practicing Clinicians Exchange. All Rights Reserved. 104922O-pod3